Compound · clinical trials

Cretostimogene Grenadenorepvec clinical trials

Also listed in trial records as CG0070

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our USA, Canada, China, Israel, Japan, South Korea, Taiwan and Australia registers that name Cretostimogene Grenadenorepvec as an intervention. Synced 10 Nov 2026

4Current trials

2Recruiting now

2Lead sponsors

8Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Cretostimogene Grenadenorepvec is named as an intervention in 4 current clinical trials in our USA, Canada, China, Israel, Japan, South Korea, Taiwan and Australia registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is CG Oncology, Inc (3). The most-studied condition is Non Muscle Invasive Bladder Cancer.

How Cretostimogene Grenadenorepvec works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

In situ carcinomaPhase 3
Urinary bladder carcinomaPhase 2
Bladder transitional cell carcinomaPhase 1
Urinary bladder cancerPhase 1

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095454, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Cretostimogene Grenadenorepvec

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting250%
Active, closed250%

Trials by phase

Phase 2250%
Phase 3250%

Clinical trials of Cretostimogene Grenadenorepvec

4 trials

Study	Phase	Status	Lead sponsor	Registers
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC NCT06567743 · High-Risk Non-Muscle-Invasive Bladder Cancer	Phase 2	Recruiting	CG Oncology, Inc	USA, Canada
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin NCT07283835 · ClinicalTrials.gov ↗ · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	Phase 2	Recruiting	Lepu Biopharma Co., Ltd	China
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin NCT04452591 · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	Phase 3	Active, closed	CG Oncology, Inc	USA, China, Canada, Japan, South Korea, Taiwan, Australia
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT NCT06111235 · Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer	Phase 3	Active, closed	CG Oncology, Inc	USA, Canada, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Cretostimogene Grenadenorepvec

6 conditions

Non Muscle Invasive Bladder Cancer3High-grade Ta/ T1 Papillary Disease Bladder Cancer2High-Risk Non-Muscle-Invasive Bladder Cancer1Urologic Cancer1Bladder Cancer1 Urothelial Carcinoma1

By country register

Register	Trials	Recruiting
Clinical trials in USA	3	1
Clinical trials in Canada	3	1
Clinical trials in China	2	1
Clinical trials in Israel	1	0
Clinical trials in Japan	1	0
Clinical trials in South Korea	1	0
Clinical trials in Taiwan	1	0
Clinical trials in Australia	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Cretostimogene Grenadenorepvec trials

How many clinical trials are testing Cretostimogene Grenadenorepvec?

4 current trials in our USA, Canada, China, Israel, Japan, South Korea, Taiwan and Australia registers name Cretostimogene Grenadenorepvec (also registered as CG0070) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Cretostimogene Grenadenorepvec trials recruiting patients?

Yes. 2 of the 4 trials are recruiting: 1 with sites in USA, 1 with sites in Canada and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Cretostimogene Grenadenorepvec clinical trials?

CG Oncology, Inc (3) and Lepu Biopharma Co., Ltd (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cretostimogene Grenadenorepvec works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cretostimogene Grenadenorepvec works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cretostimogene Grenadenorepvec (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.